See whether Helium helps you make better-informed decisions. Try every Pro Trader feature for 30 days. No credit card required.
Try every Pro Trader feature for 30 days. No credit card required.
Corporate-sponsored, pro-Delcath bias highlights retrospective European data on liver-directed melphalan perfusion (M-PHP) with CHEMOSAT, frames ongoing trials as supportive, and notes regulatory context while urging further evaluation.
A corporate press release announcing retrospective European data on percutaneous hepatic perfusion with melphalan for liver-dominant metastatic breast cancer, presented at ESMO Breast Cancer Congress 2026, and detailing regulatory statuses and an ongoing trial.
2026 © Helium Trades
Privacy Policy & Disclosure
* Disclaimer: Nothing on this website constitutes investment advice, performance data or any recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Helium Trades is not responsible in any way for the accuracy
of any model predictions or price data. Any mention of a particular security and related prediction data is not a recommendation to buy or sell that security. Investments in securities involve the risk of loss. Past performance is no guarantee of future results. Helium Trades is not responsible for any of your investment decisions,
you should consult a financial expert before engaging in any transaction.
